UNSPSC 51373448: Codeine/papaverine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373448 Codeine/papaverine is a Commodity code that in recent state and local procurement reflects broader pharmaceutical procurement across therapeutic categories, particularly naloxone and over-the-counter medications sourced through cooperative purchasing vehicles and direct county health procurements. State and local governments buy pharmaceutical products — both branded and generic multi-source medications — through two primary channels visible in recent activity: direct county health department solicitations for specific therapeutics tied to public health initiatives, and statewide or multistate cooperative purchasing agreements that establish master contracts with manufacturers for distribution through authorized wholesalers to participating state agencies, counties, and municipalities. Issuing bodies include county health departments (Seminole County, Florida) and state purchasing offices administering multistate cooperative purchasing alliances (Minnesota Department of Administration).

Activity concentrates in Florida and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinating procurement across multiple participating states including Oregon. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) effective July 1, 2026. The MMCAP procurement weights price competitiveness at 75 percent of evaluation, requires cGMP and Drug Supply Chain Security Act (DSCSA) compliance, and imposes a 3 percent administrative fee on all contract purchases.